Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.77 EUR
−126.55 M EUR
420.72 M EUR
99.30 M
About Intra-Cellular Therapies Inc.
Sector
CEO
Sharon L. Mates
Headquarters
Bedminster
Website
Founded
2002
FIGI
BBG005ZQRYG1
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 23I is 123.00 EUR — it has increased by 1.65% in the past 24 hours. Watch INTRA-CELLULAR THERAPIES INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange INTRA-CELLULAR THERAPIES INC stocks are traded under the ticker 23I.
23I stock has fallen by −1.60% compared to the previous week, the month change is a 54.72% rise, over the last year INTRA-CELLULAR THERAPIES INC has showed a 98.71% increase.
We've gathered analysts' opinions on INTRA-CELLULAR THERAPIES INC future price: according to them, 23I price has a max estimate of 136.31 EUR and a min estimate of 84.70 EUR. Watch 23I chart and read a more detailed INTRA-CELLULAR THERAPIES INC stock forecast: see what analysts think of INTRA-CELLULAR THERAPIES INC and suggest that you do with its stocks.
23I stock is 1.64% volatile and has beta coefficient of 0.70. Track INTRA-CELLULAR THERAPIES INC stock price on the chart and check out the list of the most volatile stocks — is INTRA-CELLULAR THERAPIES INC there?
Yes, you can track INTRA-CELLULAR THERAPIES INC financials in yearly and quarterly reports right on TradingView.
INTRA-CELLULAR THERAPIES INC is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
23I earnings for the last quarter are −0.22 EUR per share, whereas the estimation was −0.16 EUR resulting in a −39.48% surprise. The estimated earnings for the next quarter are −0.06 EUR per share. See more details about INTRA-CELLULAR THERAPIES INC earnings.
INTRA-CELLULAR THERAPIES INC revenue for the last quarter amounts to 157.51 M EUR, despite the estimated figure of 154.75 M EUR. In the next quarter, revenue is expected to reach 187.52 M EUR.
23I net income for the last quarter is −23.64 M EUR, while the quarter before that showed −15.14 M EUR of net income which accounts for −56.13% change. Track more INTRA-CELLULAR THERAPIES INC financial stats to get the full picture.
No, 23I doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 23, 2025, the company has 610.00 employees. See our rating of the largest employees — is INTRA-CELLULAR THERAPIES INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTRA-CELLULAR THERAPIES INC EBITDA is −108.75 M EUR, and current EBITDA margin is −34.21%. See more stats in INTRA-CELLULAR THERAPIES INC financial statements.
Like other stocks, 23I shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTRA-CELLULAR THERAPIES INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INTRA-CELLULAR THERAPIES INC technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INTRA-CELLULAR THERAPIES INC stock shows the strong buy signal. See more of INTRA-CELLULAR THERAPIES INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.